BioPharma Clinical Trials
NueCell Bio Joins CIRM Partnership to Accelerate Cell and Gene Therapies from Discovery to GMP Readiness
NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness, announced it has joined the ...
October 15, 2026 | News
China’s Hiteck Biological Pharma Licenses Next-Generation Eye Therapy to Visara for Global Development
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has entered into an exclusive license agreement (the "License Agreement") with Visara, Inc...
October 15, 2026 | News
Suvoda Expands Sofia AI Assistant Across New Clinical Trials to Accelerate Study Operations
Clinical trials require guard railed AI that's purpose built for the regulated industry that has high human stakes and required audit trails. Sofia help...
October 13, 2026 | News
South Korea’s GCCL and LabConnect Partner to Strengthen Global Clinical Trial Operations Across APAC and North America
GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that it signed a Memorandum of ...
October 14, 2026 | News
Shanghai Ark Biopharmaceutical Secures US FDA IND Clearance for Phase II Trial of Long-Acting Influenza Prevention Drug AK0406
Shanghai Ark Biopharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK...
October 14, 2026 | News
CellCarta Partners with Waters Corporation to Advance Companion Diagnostics and Next-Generation Flow Cytometry
CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, announced a strategic partnership with Waters Corporation, a global lea...
October 14, 2026 | News
360biolabs Expands Australian Footprint with New Bioanalytical Laboratory in Sydney
The new 360biolabs facility in North Ryde is strategically located within one of Sydney’s vibrant science and medtech hubs, Macquarie Park In...
October 14, 2026 | News
Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA
Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...
October 13, 2026 | News
Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy
Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening...
October 13, 2026 | News
12 APAC-Originated Programmes to Watch at ESMO 2026
When the ESMO Congress 2026 opens at IFEMA Madrid on Friday 23 October, the region that most European oncologists still think of as a fast follower will ho...
October 13, 2026 | News
Innovent’s SYCUME Meets Primary Endpoint in Phase III Trial for Inactive Thyroid Eye Disease in China
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
October 12, 2026 | News
Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) ev...
October 12, 2026 | News
Resonant Clinical Solutions and Haier Biomedical Launch Eco-Friendly Centrifuge for Clinical Trials
Resonant Clinical Solutions – a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lif...
October 09, 2026 | News
OncoBayes’ OB-001 Shows Potential to Overcome ADC Resistance and Boost Brain Penetration of Cancer Drugs
OncoBayes, a privately held clinical-stage pharmaceutical company, announced the successful completion of preclinical work with OB-001, demonstrating the p...
October 08, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
